Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
LOGIN
REGISTER
SEARCH
Home | go to homepage
LOGIN
REGISTER
SEARCH
Home | go to homepage
SCIENCE
  • SCIENCE
  • Allergic Rhinitis
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Allergic Rhinitis
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovasc®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Plavix®
  • Praluent®
    • Praluent®
    • Praluent®
    • Praluent 300 mg
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
  • LOGIN
  • REGISTER
  • SEARCH
    • Home
    • Science
    • Cardiovascular
    • Atherothrombosis

    Atherothrombosis

    Discover more on science updates, events, KOLs interviews and more on Atherothrombosis

    Science in Atherothrombosis

    Get a 360º view and stay up-to-date on Atherothrombosis with content selected for you

    In hospital outcomes in young patients with AMI: Results from Gulf Coast

    Adherence and persistence analysis in patients treated with DAPT

    Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

    Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

    Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

    SEE EVERYTHING

    Inspiration and innovation

    Get inspired and stay at the forefront of innovation with the following resources

    Understanding de-escalation in antiplatelet therapy

    Single antiplatelet therapy Insights on earlier use

    Management of antithrombotic therapy in patients with AF undergoing PCI

    Clopidogrel as the standard of care for elective PCI: Findings from the ALPHEUS

    SEE EVERYTHING
    Home | go to homepage

    SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318,

    Fax: +966-12-663-6191

    For Medical Information, please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com

    To report any Product Technical Complaints, kindly contact: Email: quality.greatergulf@sanofi.com

    In case of any drug related adverse events, please contact:

    The National Pharmacovigilance Center (NPC):

    Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa/

    And Sanofi Pharmacovigilance Department:

    Phone: +966-544-284-797, E-mail: Ksa_pharmacovigilance@sanofi.com

     

    MAT-SA-2100978/V4/NOV 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.